In a double-blind, placebo-controlled trial in 29 patients with severe atopic eczema, ten weeks of thymostimulin improved clinical scores at three months, but the difference did not last and immunological measures did not change.
emerging — human data exists, and it is thin or contested
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
In a double-blind, placebo-controlled trial in 29 patients with severe atopic eczema, ten weeks of thymostimulin improved clinical scores at three months, but the difference did not last and immunological measures did not change. · pmid:1835403
Classification
Thymostimulin (TP-1) is a polypeptide extract of thymus. · pmid:1835403
Mechanism
In mice with Lewis lung carcinoma, thymostimulin delayed the primary tumour and, after the tumour was removed or together with chemotherapy, increased survival and the share of mice that stayed tumour-free for six months. · pmid:7248976
Identity
No public registry record is shown for this page: PubChem gave no record that proves it is this substance.
Where the evidence actually sits
Emerging50%
Preclinical only50%
Proportion of the 2 claims about Thymostimulin (TP-1) standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Thymostimulin (TP-1) yet.
Dose evidence, rung by rung
No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
nothing resolved on this rung
Observational evidence· resolved human data at the emerging tier: thin, or contested
A double-blind placebo-controlled study of thymostimulin (TP-1) for the treatment of atopic eczema. · pmid 1835403 · 1991
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
Effect of the thymic factor, thymostimulin (TP-1), on the survival rate of tumor-bearing mice. · pmid 7248976 · 1981
2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.